This study H0P -MC- OA03 ([STUDY_ID_REMOVED]) is a sub -study of Master Protocol H0P -MC-CPMP 
([STUDY_ID_REMOVED]) 
 
Protocol: H0P -MC-OA03(a)  
 Randomized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of 
Osteoarthri�s Pain  
 [STUDY_ID_REMOVED]   Approval Date: 03 -Mar -2021 
C O N FI D E N TI A L  Pr ot oc ol n u m ber H 0 P -M C -O A 0 3 (a) 
 1 Title P a ge  
C o nfi d e nti al I nf or m ati o n  
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s. It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli n i c al 
i n v e sti g ati o n of L Y 3 5 5 6 0 5 0 u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s.  
 
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o an y 
p u bli c r el e a s e. I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
 
M aster Pr ot oc ol Title:  A Master Pr ot oc ol f or Ra n d o mize d, Place b o - C o ntr olle d, P hase 2 
Cli nical Trials of M ulti ple I nter ve nti o ns f or t he Treat m e nt of C hr o nic Pai n  
M aster Pr ot oc ol N u m ber: H 0 P -M C -C P M P  
I S A Title: Ra n d o mize d, Place b o - C o ntr olle d, P hase 2 Cli nical Trial t o E val uate L Y 3 5 5 6 0 5 0 f or 
t he Treat me nt of Oste oart hritis Pai n 
I S A N u m ber: H 0 P -M C -O A 0 3  
A me n d me nt N u m ber: a 
C o m p o u n d : L Y 3 5 5 6 0 5 0 St u d y P h ase: 2 
S h ort Title:  Cli nical Trial t o E val uate L Y 3 5 5 6 0 5 0 f or t he Treat me nt of Oste oart hritis Pai n  
Acr o n y m : O A 0 3 S p o ns or N a me: Eli Lill y a n d C o m pa n y  
Le g al Re gistere d A d dress: I n dia na p olis, I n dia na, U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber :   
Master Pr ot oc ol I N D 1 4 4 9 1 5 
L Y 3 5 5 6 0 5 0 I N D 1 2 9 7 5 6 
A p pr o v al D ate: Pr ot oc ol  a me n d me nt (a) Electr o nicall y  Si g ne d a n d A p pr o ve d b y Lill y o n date 
pr o vi de d bel o w.  
  
A p pr o v al D at e: 0 3- M ar- 2 0 2 1 G M T
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol number H0P-MC-OA03(a) 
 3  Protocol Amendment Summary of Changes Table 
 
DOCUMENT HISTORY 
Document Date 
Original Protocol 25 August 2020 
Amendment [a]  
Overall Rationale for the Amendment: 
This amendment addresses a new  dose titration scheme for partic ipants.  
 and decisions to change the  dose level will be made by t he investigator, in discussion 
with the participants, based on adverse events reported for tolerability. The changes for dose 
titration affect sections thr oughout the ISA. Additional update s were made according to 
emerging data and changes t o the master protocol. 
Section # and Name Description of Change Brief Rationale 
1.1 Synopsis Updates made to 
 Number of Participants 
 Intervention Groups and 
Duration, and 
 Data Monitoring Committee Sample size and study intervention text updated for new dose titration scheme “Data monitoring committee” changed to “Assessment committee” for consistency with 
master CPMP protocol 
1.2 Schema Updated schema to show dose 
titration  New dose titration scheme for participants 
1.3 Schedule of Activities (SoA) Added telephone visits and updated study intervention notes 
to include a link to the new dose modification section To implement new dose titration scheme 
1.3 Schedule of Activities (SoA) Updates were made to ECG and Vital signs Corrections for clarity 
1.3 Schedule of Activities (SoA) Replaced urinalysis with urine drug screen. Urinalysis was only for Visit 3, so removed. Urine drug screen added and p erformed according to 
investigator discretion 
1.3 Schedule of Activities (SoA) Added window for PK sample collection Adding flexibility 
1.3 Schedule of Activities (SoA) Added participant digital biomarker device for Visit 7 and ED To indicate when the particip ant needs to return the 
device. 
2.2 Background Updated information for the 2 
Phase 1 clinical studies Both studies are completed 
4.1 Overall Design Updated and added text to 
describe the new dose titration scheme New dose titration scheme for participants 
4.3 Justification for Dose Added text for the titration scheme 
Removed “preliminary” from the 
beginning of second paragraph New dose titration scheme for participants  
Study LXBA is now completed 
5.2 Exclusion Criteria Updated Criteria #1028 and Clarification s based on clinical experience and 
CCI
CONFIDENTIAL Protocol number H0P-MC-OA03(a) 
 4  Section # and Name Description of Change Brief Rationale 
#1034 emerging pharmacokinetic/metabolism data 
5.3 Lifestyle 
Considerations  Removed text that is already in the master CPMP Master protocol updates for CPMP amendment (a) 
6.1 Study Intervention(s) Administered Updated text and table New dose titration scheme for participan ts. 
Emerging data allow partic ipants to take capsules 
with or without food Changed “pharmacy instructions” to “pharmacy manual” 
6.5 Concomitant Therapy Removed text that is duplicated in CPMP Added text for drug-drug 
interactions Consistency across ISAs 
6.6 Dose Modification New section New dose titration scheme for  participants  
8.2 Adverse Events and 
Serious Adverse Events Added text to refer to the master Master protocol contains AE a nd SAE information 
9.2 Sample Size Determination Updated sample size New dose titr ation scheme for participants 
9.3 Populations for Analyses Removed “in the SAP” The master protocol defines the population s for 
analyses 
10.2 Appendix 2  Updated text Updates to internal Lilly guidance 
Throughout the protocol Minor editorial and formatting changes Minor, therefore not described 
 
  
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
5Table of Contents
1. Protocol Summary ...................................................................................................... 7
Synopsis ....................................................................................................................... 7
Schema ......................................................................................................................... 8
Schedule of Act ivities (SoA) ........................................................................................ 9
2. Introduction .............................................................................................................. 13
Study  Rati onale .......................................................................................................... 13
Background ................................................................................................................ 13
Benefit/Risk Assessment ............................................................................................ 14
2.3.1. Risk Assessment ......................................................................................................... 14
2.3.2. Benefit Assessment ..................................................................................................... 14
2.3.3. Overall Benefit:  Risk Conclusio n............................................................................... 15
3. Objectives and Endpoints ......................................................................................... 16
4. Study Design ............................................................................................................. 17
Overall Design............................................................................................................ 17
Scientific Rati onale f or Study  Design ......................................................................... 18
Justification for Dose .................................................................................................. 18
End of Study  Defini tion.............................................................................................. 18
5. Study Population ...................................................................................................... 19
Inclusio n Cri teria........................................................................................................ 19
Exclusio n Cri teria....................................................................................................... 19
Lifest yle Considerat ions............................................................................................. 20
6. Study Intervention .................................................................................................... 21
Study  Intervent ion(s) Administered ............................................................................ 21
Preparati on/Handling/Storage/Accountabilit y............................................................. 21
Measures to Minimize Bias:  Rando mizat ion and Blinding ......................................... 22
Study  Intervent ion Compliance ................................................................................... 22
Concomitant Therapy ................................................................................................ .22
Dose Modificat ion...................................................................................................... 22
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Wit hdrawal .................................................................................... 24
Discontinuati on of  Study  Intervent ion........................................................................ 24
8. Study Assessments and Procedures ......................................................................... 25
Safety Assessments .................................................................................................... 25
8.1.1. Vital Signs.................................................................................................................. 25
8.1.2. Electrocardiograms ..................................................................................................... 25
8.1.3. Clinical Safety  Laboratory  Assessments ..................................................................... 25
Adverse Events and Serious Adverse Events .............................................................. 25
Treatment of Overdose ............................................................................................... 25
Pharmacokinet ics........................................................................................................ 25
Pharmacodynamics ..................................................................................................... 26
................................................................................................................. 26
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
69. Statistical Considerations ......................................................................................... 27
Statistical Hypotheses ................................................................................................ .27
Sample Si ze Determinat ion......................................................................................... 27
Popul ations for Analyses ............................................................................................ 27
Statistical Analyses ..................................................................................................... 27
9.4.1. General Considerations ............................................................................................... 28
9.4.2. Pharmacokinet ics and Pharmacodynamics .................................................................. 28
9.4.3. Terti ary/Expl oratory ................................................................................................... 28
9.4.4. Biomarkers ................................................................................................................. 28
Interim Ana lyses ......................................................................................................... 28
10. Supporting Documentation and Operational Considerations ................................ 29
Appendix 1:  Clinical Laboratory  Tests ....................................................................... 29
Appendix 2:  Definit ions of Reproductive Requirements and 
Contraceptive Guidance .............................................................................................. 30
Appendix 3:  Provisio ns for Changes in Study  Conduct During 
Except ional Circumstances ......................................................................................... 34
Appendix 4:  Abbreviat ions........................................................................................ 37
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
71. Protocol Summary
Synopsis
Protocol Title: Rando mized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate 
LY35 56050 for the Treatment of Osteoarthrit isPain
Rationale:
The purpose of this study  is to test whether LY3556050 is efficacious in relieving osteoarthri tis 
(OA)pain in the knee . Data will be collected to assess the safet y and tol erabilit y of LY3556050
in this study  popul ation. Pharm acokinet ic properti es and pharmacodynamic effects will also be 
explored . The totalit y of data from  this proof -of-concept study will assess the benefit s and risks
associ ated wi thLY3556050 and inform decisio ns for the clinical development of LY3556050 .
Objectives and Endpoint s:
The primary  and secondary  object ives and endpo ints are stated in the master protocol 
H0P- MC-CPMP (CPMP) and OA disease -state addendum (DSA; CPMP[1]).
Overall Design :
This is an
8-week, Phase 2,randomized, double -blind, pl acebo -controlled study that will 
compare LY3556050 versus placebo in participants with OA in the knee .
Disclosure Statement :This is a randomized, investigator- and participant -blind, 
placebo -controlled, Phase 2 clinical trial.
Number of Participant s:
Up to 200 participants will be rando mized in a  ratio toLY3556050 and placebo , respectively ,
with the assumpt ion that approximately 33 % of  the parti cipants will drop out prior to the end of 
the double -blind treatment peri od. 
Intervention Groups and Duration :
Parti cipants will receive eit her LY3556050 or placebo. Based on tolerabilit y, participants may
take up to a maximum of 3 capsules orally (each capsule is ), twice daily, approximately  
every 12 hours ,for a total  dose of 600 mg.  
This is an 8 -week study .
Data Monitoring Committee: Yes.  
Safety reviews are covered by  the Assessment Committee charter for the Chronic Pain Master 
Protocol .
CCI
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
8
CCI
CCI
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
9
Schedule of Activities (SoA)
This SoA shows visits and procedures unique to the intervent ion-specific appendix (ISA) H0P -MC-OA03 (OA03) for LY3556050. 
Please refer to m aster protocol  CPMP and the OA DSA CPMP(1) SoAs for addit ional informat ion.  
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
10H0P-MC-OA03
ISARandomization Double -Blind Treatment Early
Discontinu
ationNotes
Visit Number V3 V4 V5 V6 V7 ED
Study Week 0 2 4 6 8
Visit Window (days) ±3 ±3 ±3 ±3
Telephone visit Xa,bVisit window +2 days
There will be 2 telephone visits between Visit 3 and Visit 4:
aVisit occurs 4 days after Visit 3  
bVisit occurs 8 days after Visit 3  
  
Procedures
Evaluate all I/E criteria X
Physical examination X X X X X X V3- V7:  Do symptom -direct edphysical examination
ECG X X X X X X V3, V5 and V7:  Single ECG b efore in-clinic dosing and at 3 hours after 
dosing
V4, V6 and ED :  Single ECG
ECG includes c ollection of PR interval, QRS duration and interval, and heart 
rate.
Vital signs X X X X X X Blood Pressure
V3, V5,and V7: Collect b lood pressure and pulse i n supine and standing 
position , before in -clinic dosing and at 3 hours after dosing
V4, V6 and ED:  Collect b lood pressure once
Collect o rthostatic blood pressure after 5 minutes supine and then 2 -3minutes 
after standing and collect pulse after supine and standing blood pressure .
Temperature and Respiratory rate
Collect once at each visit
CCI
CCI
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
11H0P-MC-OA03
ISARandomization Double -Blind Treatment Early
Discontinu
ationNotes
Visit Number V3 V4 V5 V6 V7 ED
Study Week 0 2 4 6 8
Visit Window (days) ±3 ±3 ±3 ±3
Telephone visit Xa,b
Study  intervention X X X X X Intervention is taken orally, twice daily (BID) , approximately every 12 hours .
V3, V5,and V7:  Participants take the m orning dose in the clinic .
Refer to Section 6.6for dose titration scheme .
Intervention compliance X X X X X
Laboratory Tests and Sample Collection
Hematology X X X X X X
Chemistry X X X X X X
Urine drug screen Performed at investigator discretion
Serum pregnancy X X X X X For WOCBP only
Urine pregnancy X For WOCBP only
Collect sample within 24 hours prior to first dose .
Lipid panel X X X X X X
Thyroid panel X X X X X X
Cystatin C X X X X X X
CCI
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
12H0P-MC-OA03
ISARandomization Double -Blind Treatment Early
Discontinu
ationNotes
Visit Number V3 V4 V5 V6 V7 ED
Study Week 0 2 4 6 8
Visit Window (days) ±3 ±3 ±3 ±3
Telephone visit Xa,bVisit window +2 days
There will be 2 telephone visits between Visit 3 and Visit 4:
aVisit occurs 4 days after Visit 3  
bVisit occurs 8 days after Visit 3  
  
HbA1c X X
PK sample X X X X X X V3:  Collect 3 hours ±15minutes after dosing.
V5 and V 7:  Collect samples before dosing and 3 hours ±15minutes after 
dosing .
V4,V6,and ED :  Collect s ingle sample at any time.
Record date and time of collection.
Somatostatin -related
biomarker sampleX X X X X X
Participant Device
Participant returns device X X
Abbreviations:  ECG = electrocardiogram; ED = early discontinuation; HbA1c = glycated hemoglobin ;I/E = inclusion and exclusion; ISA = intervention -specific 
appendix ;PK=pharmacokinetic ;V = visit; WOCBP = women of childbearing potential .
CCI
CCI
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-OA03(a) 
 13 2. Introduction 
This ISA, H0P-MC-OA03 (OA03), is an appendix to the master protocol CPMP and contains 
unique study elements specific for LY3556050. The master protocol contains the overarching 
study elements that govern the OA DSA CPMP(1) and this ISA OA03.   
 Study Rationale 
The purpose of this study is to test whether LY3556050 is efficacious in relieving OA pain in the 
knee. Data will be collected to assess the safety and tolerability of LY3556050 in this study 
population. Pharmacokinetic (PK) properties and pharmacodynamic (PD) effects will also be 
explored. The totality of data from this proof-of-concept study will assess the benefits and risks 
associated with LY3556050 and inform decisions for the clinical development of LY3556050.  
 Background 
Somatostatin (SST) is an inhibitory neuropeptide exerting its activity via 5 different SST 
receptor (SSTR) subtypes, named SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5. Most are 
involved in homeostatic regulation of polypeptide hormones. Given its neuronal distribution, 
SSTR4 has been of interest for its ability to modulate sensory nerve transmission and pain 
response.   
LY3556050 is a selective, potent, and full agonist of the human SSTR4 and is under 
development as an oral analgesic for chronic pain. A detailed description of the chemistry, 
pharmacology, PK, and safety of LY3556050 is provided in the Investigator’s Brochure (IB).   
Two Phase 1 clinical studies in healthy participants are completed, CNTX-0290-101 (CNTX) 
and J2P-MC-LXBA (LXBA). The CNTX and LXBA study results are available in the IB.   
Pharmacokinetics 
The PK data from Study LXBA Part A were consistent with those observed in Study CNTX and 
support twice-daily dosing. 
Safety 
The highest dose of 600 mg every 12 hours is considered safe and well-tolerated in healthy 
participants. 
  
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
14
Benefit/Risk Assessment
The IB provides detailed informat ion about the known and expected benefit s and risks and 
reasonab ly expected adverse events ( AEs)of LY3556050.   
2.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention LY35 56050
Cardiovascular HR: Variable data across clinical 
studies and across doses
PR interval : Concentration -related 
increase in duration with large 
variability
QRS interval : Concentration -related 
increase in durationVital signs and ECGs evaluated at 
each visit . Cardiovascular safety 
parameters to be evaluated include:
HR, PR and QRS intervals, and 
orthostatic vital signs.
Additional participant exclusion 
criteria to protect those with a 
potential risk.
Discontinuation criteria for clinically 
significant changes.
Thyroid TSH increases observed in 
Study LXBALabs evaluated at each visit to
monitor thyroid function .
Additional participant exclusion 
criteria to protect those with a 
potential risk.
Discontinuation criteria for clinically 
significant changes.
Abbreviations:  ECG = electrocardiogra m; HR = heart rate; TSH =thyroid- stimulating hormone .
2.3.2. Benefit Assessment
This is the first study evaluat ing efficacy of LY3556050 in participants wi th OA.
Potenti al benefi ts for the study  parti cipants include 
study -related medical procedu res 
ophysical examinat ions, 
olaboratory  tests 
oelectrocardi ogram s (ECGs) 
detailed evaluat ions of OA 
oknee examinat ions 
oknee x-rays, and
OA-associ ated questi onnaires that m ay improve parti cipants understanding of their own 
condi tion. 
As part of the master protocol CPMP, parti cipants to this ISA will report their experience susing 
standard tool s that will contribute to the assessment of novel treatments for OA.  In addition, data 
collected from this study  may also improve our understanding of chronic pain. Together, th ese
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
15may lead to the development of a new treatment wit h an improved safety  and efficacy  profile 
compared to standard of care.
2.3.3. Overall Benefit:  Risk Conclusion
The measures taken to minimize risk to participants in this study andthe pote ntial risks identified 
in associat ion with ISA OA0 3are justified by the ant icipated benefits to participants with OA.
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
163. Objectives and Endpoints
The m aster protocol  CPMP and OA DSA CPMP(1) include object ives and endpo ints applicable 
for this study . This tab le describes objectives and endpo ints specific for LY3556050.
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
174. Study Design
Overall Design
Master protocol CPMP describes the overall study  design and study  design rati onale. This 
section descri bes visits and overall procedures unique to ISA OA0 3for LY3 556050 in addit ion 
to the procedures outlined in master protocol CPMP and DSA CPMP(1) .  
Double -Blind Treatment Period (Visits 3 through 7)
If the participant receives at least 1 dose of intervent ion and discont inues during the double -blind 
treatm ent peri od, they  shoul d com plete early  discontinuat ion procedures per the master 
protocol CPMP, OA DSA CPMP(1), and th eOA03 Schedule of Activit ies (SoA). If there are 
duplicate procedures, fo llow the OA03 SoA.
Visit 3
At Visit 3 post randomization
the site completes the OA03 baseline procedures and sample co llection 
participants receive their first dose of study  intervent ion and instructi ons for dosing at 
home
the site completes all post treatm ent sam ple collecti on and safety  monitoring , and
the site instructs participants to continue with study restrict ions and Numeric Rat ing 
Scale (NRS) di ary entri es before thei r visit discharge.
Telephone Visit s
Visit 3 +4 days
Four days after Visit 3, with a window of +2 days , parti cipants will complete a telephone visit 
with the si te.  
The site will review available safet y data and study  intervent ion compliance.  
The invest igator in discussi onwith participant will determine if the dose will be increased or if
the participant will be discont inued .  
Visit 3 + 8 days
Eightdays after Vi sit 3, with a window of +2 days, participants will co mplete a telephone visit 
with the si te.  
The site will review available safet y data and study  intervent ion compliance. 
The i nvest igator in discussion wit h parti cipant will determine if the dose will be increased or if 
the participant will be discont inued.
Dose m odificat ion gui dance i s provi ded in Sect ion 6.6.
CONFIDENTIAL  Protocol number H0P -MC-OA03 (a) 
 18 Visit 4  
Visits 4 through 7  
At Visits 4 through 7, the site  
 reviews available safety data and completes predose procedures and sample collection  
 reviews diary  compliance  
 reviews study intervention compliance 
 completes all posttreatment sample collection and safety monitoring , and 
 instructs participants to continue with study restrictions and NRS diary entries before 
their visit discharge .  
 
 Scientific Rationale for Study Design 
The master protocol describes the overall study design rationale.  
Section 2.3 describes elements included in this study to furthe r monitor cardiovascular and 
thyroid function, and the associated rationale.    
 Justification for Dose  
The dose level of 600 mg twice daily (BID) was determined by current clinical data, efficacy 
pharmacology, and nonclinical safety data detailed in the IB. A titration scheme is included to 
maximize tolerability of this target dose.   
Safety data from Study LXBA, and the clinical monitoring plan for this ISA, support testing the 
proposed dose regimen in participants with chronic pain conditions. 
The observed LY 3556050 exposure following repeated administration of 600 mg BID exceeds 
the exposure in  rats where  maximal  pharmacological activity was consistently demonstrated 
across rodent models of neuropathic pa in. However, it is not known what exposure is required  
for efficacy in the target patient population. Therefore, the highest dose ( 600 mg BID ) previously 
evaluated  in Study LXBA was selected for this study as this dosing regimen  was observed to be 
well-tolerated  in healthy subjects and supported by an adequate margin of safety , based on both 
monkey and rat repeated-dose toxicity studies ( IB).  
 End of Study Definition  
A participant is considered to have completed th is ISA if he  or she has completed all required 
phases of the study including the last scheduled procedure shown in the ISA SoA . 
The end of the study is defined as the date of the last visit of the last participant in the study or 
last scheduled procedure shown in the ISA SoA  for the last participant.  
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
195. Study Population
The m aster protocol  CPMP and OA DSA CPMP(1) provide eligibilit y criteria that m ust be
followed for thi s study . LY3556050 specific inclusio n and exclusio n criteria are listed here.
Inclusion Criteria
Parti cipants are eligible to be included in the study only if all the fo llowing cri teria apply:
[1025] are men or women who abide by the repro ductive and contraceptive requirements 
provi ded in OA03 Secti on 10.2, Appendix 2.
Women of childbearing potential (WOCBP) may parti cipate and include those 
who
are com pletely  abstinent or in a same -sex relat ionship, as part of their 
preferred and usual lifest yle, must agree to either remain abst inent or stay in 
a sam e-sex rel ationship wit hout sexual relat ionships with males, or 
must agree to use 1highly effe ctive m ethod of contracepti on (less than 
1%failure rate), or a combination o f 2 effect ive methods of contraception, 
for the enti rety of the study .  
Womennot of childbearing potential may participate and include those who 
have a congenital ano maly such as Müllerian agenesis 
areinfert ile due to surgical sterilizat ion, or 
are postmenopausal.  
Exclusion Criteria
Parti cipants are excl uded fro m the study  if any of the fo llowing cri teria apply:
Medical Conditions
[1026] have a history  within 2 years prior to Vi sit 1or current evidence of syncope, 
presyncope, uncontrolled vertigo, or postural dizziness, judged to be clinically 
significant by  the invest igator
[1027] have a QRS interval ≥120 msec at Visi t 1 or Vi sit 2
[1028] have a non-evaluable PR interval or a PR interval >200 m secat Visi t 1 or Vi sit 2
[1029
] have a heart rate <40 bpm at Visit 1 or Visit 2
[1030] have an estimated glomerular filtration rate (eGFR) of less than 
60ml/min/1.73 m2based on the Chronic Kidney D isease Epidemio logy 
Collaboration ( CKD -EPI) formula at Vi sit1 or Visi t 2
[1031] have clinically  significan tactive thyro id disease , including Hashimoto’s 
thyroiditis
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
20Prior/Concomitant Therapy
[1032] have been on thyroid repl acement therapy or supplements for lessthan 12weeks
or had a change in thyro id replacement therapy or supplements in the last 
12weeks before Visit 2
[1033] have had a change in beta blocker therapy in the last 12 weeks before Visit 2. This 
does not i nclude a discont inuat ion of therapy .
[1034] are taking medicat ions that are known MATE1 or OCT2 substrates with the risk 
for potenti ally clinically significant drug -drug i nteracti ons, such as metformin, 
dofetilide and dalfa mpridine
Other Exclusions
[1035] are pregnant or breastfeeding .
Lifestyle Considerations
Reproductive and Contraception Requirements
Reproductive requirements and contraceptive guidance are provided in OA0 3Section 10.2, 
Appendix 2.Participants shoul d maintain a consistent lifest yle throughout participat ion as much 
as possible. Refer to master protocol CPMP Section 5.3 for addit ional details.  
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
216. Study Intervention
Study I ntervention(s) Administered
Parti cipants will take capsules orally BID, approximately every 12 hours ,with or without food .  
Intervention Name LY3556050 Placebo
Dose Formulation capsule capsule
Unit Dose 
Strength(s)/capsule Not applicable
Dosage Level(s)  mg BID, approximately 
every 12 hoursPlacebo match BID
Route of 
Administrationoral oral
Use experimental placebo
IMP and NIMP IMP IMP and NIMP
Sourcing LY3556050 from Lilly Placebo will be packaged, labeled, distributed, and 
dispensed as IMP by Lilly
Packaging and 
LabelingIn bottles In bottles
Abbreviations:  BID = twice daily; IMP = investigational medicinal product; NIMP = non -investigational medicinal 
product.
Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate storage conditions have been maintained 
during transit for all study  intervent ion received and any  discrepancies are reported and resolved 
before use of the study  interventi on.
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
staff may supply or administer study  intervent ion. All study  intervent ion must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the l abeled storage condi tions wi th access limi ted to the invest igator and authorized site 
staff.
The invest igator or designee is responsible for study intervent ion accountabilit y, reconciliat ion, 
and record maintenance , that i s, recei pt, reconciliatio n, and final disposit ion records.
The pharmacy manual contain s further gui dance and informat ion for the final disposit ion of 
unused study  intervent ions.
CCI
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
22
Measures to Minimize Bias: Randomization and Blinding
This ISA contains n o addi tional stratificat ion factors.
Study Intervention Compliance
A record of the number of LY3556050 or matching placebo capsules dispensed to and taken by  
each parti cipant m ust be m aintained and reconciled with study  intervent ion and co mpliance 
records.  Intervent ion start and stop dates, including dates for intervent ion delays will also be 
recorded in the case report form ( CRF ).
Concomitant Therapy
The m aster protocol  CPMP provi des details on concomitant therapy . Conco mitant therapy  use 
shoul d remain consistent throug hout the study unless changes are medically warranted. Please 
consult the medical mo nitor for questi ons.  
Potential Drug -Drug Interactions with LY3556050
Please refer to Section 5.2for exclusio n criteria, the IB and Manual o f Operati ons f or details on 
concomitant medicat ion restrict ions.
Dose Modification
This protocol allo ws changes to the dose for individual participants , but the m aximum  daily  dose 
will not exceed 600 mg BID.
.  
Decisio ns to change the dose l evel will be made by the investigator in discussio n with the 
participants based on the adverse events reported for tolerabilit y. The medical  monitor shoul dbe 
contacted as needed.   
 
 
CCI
CCI
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
23
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
247. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Master p rotocol CPMP provides the reasons and procedures for discont inuat ion of intervention 
and participant discont inuat ion that must be followed for this study . LY3 556050- specific 
inform ation is included here. 
Discontinuation of Study Intervention
Cardiovascular Safety
A parti cipant m ay be perm anent ly discont inued from study  intervent ionfor clinically significant 
or symptomat ic cardiovascular findings including
QTcF >500 msec
PR interval prolongati on >240 msec wit h symptoms
symptomat ic sustained tachycardia ( >120 bpm )or bradycardia (<45bpm) at rest
development of a new left bundle branch block, and 
Mobi tz type II second -orthird-degree atrioventricul arblock .
Thyroid Safety
If thyroid-stimulat ing hormone ( TSH ) ≥10 at 2 consecut ive visits , then a parti cipant will be 
perm anent ly discont inued fro m study  interventi on.
If participants have TSH ≥10 at 2 consecut ive visits, then 
collect thyroid kit samples
conduct a thyroid ultrasound approximately  2 weeks after the second laboratory  time
point , and 
continue t esting unt il issue resolut ion.
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
258. Study Assessments and Procedures
Study  procedures and thei r timing are summarized in the master protocol CPMP, OA DSA 
CPMP(1), and ISA OA0 3 SoAs. 
LY3556050- specific assessments and procedures are described here. 
Safety Assessments
The SoA contains the p lanned time points for all safet y assessments.
8.1.1. Vital Signs
Conduct vital signs measurements for each participant according to the SoA (Section 1.3). 
Follow the study -specific reco mmendat ions included in the Manual of Operat ions.  
8.1.2. Electrocardiogr ams
Single 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using an ECG 
machine that automat ically calculates the heart rate and measures PR, QRS, QT, and QTcF
intervals. 
8.1.3. Clinical Safety Laboratory Assessments
See OA0 3Secti on 10.1 (Appendix 1)for the list of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequency for ISA OA0 3.
Adverse Events and Serious Adverse Events
The m aster protocol  CPMP(a) provi des details on adverse event (AE) and serious adverse event 
(SAE) collection, evaluat ion and fo llow-up, and SAE reporti ng.
Treatment of Overdose
There i s no known ant idote for LY3556050 overdose.
In case of suspected overdose, participants should be mo nitored for any  signs or symptom s of 
adverse reactions or effects, and supportive care should be provided as necessary. 
Pharmacokinetics
Collect v enous bl ood samples o f approximately  2mL as specified in the SoA .  
A maximum of 3samples m ay be collected at additional t ime po ints during the study if 
warranted and agreed upon between the invest igator and the sponsor.
Lilly will provide i nstructi ons for the coll ection and handling of bio logical samples. 
Site personn el will record
the date and time (24-hour cl ock time) of LY3 556050 administration inthe morning
during both in-clinic and at hom e dosing , and
the date and time (24 -hour cl ock time) of each PK sampl e.
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
26Pharmacokinet icsamples will be retained for a maximum of 2 years fo llowing last subject visit 
for the study .  
 
Pharmacodynamics
Pharmacodynamic biomarkers have not been identified to date. Data from this study will be used 
to further evaluate the PD of LY3556050 .
CCI
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
279. Statistical Considerations
The m aster protocol  and OA DSA provide statist ical considerat ions. LY3 556050- specific 
considerations are described here.
Statistical Hypotheses
The m aster protocol  CPMP describes the primary  hypothesis. 
 
 
The DSA CPMP(1) describes the secondary  hypothesis. The key  secondary  null hypothesis is 
that there i s no difference between LY3556050 and placebo on the key  secondary  endpoint, the 
mean change fro m baseline to endpoint for the WOMAC ®Pain Subscale Score.  
Sample Size Determination
Up to 200 participants will be rando mized in a  ratio toLY3556050 and placebo , respectively .
Assuming anoverall dropout rate of approximately  33%,  
 
. 
 
 
If the re is no treatment difference between placebo and LY3 556050, the probabilit y of passing 
the efficacy  criterion specified above (i .e., falsepositive) is less than 0.1. The simulat ion for the 
power cal culat ion and sa mple size determinat ion was carried out using the Fixed and Adaptive 
Clinical Trial Simulator ( FACTS )Versi on 6.0.
Populations for Analyses
The master protocol  CPMP defines the popul ations for analyses .
The PK populati on includes all rando mized participants who received a dose of LY3 556050 and 
have at least 1 evaluable PK sample. 
Statistical Analyses
Any change to the data analysis methods described in th is ISA will require an amendment only if 
it changes a principal feature of the ISA. Any othe r change to the data analysis methods 
described, and the just ificat ion for making the change, will be described in the statistical analysis 
plan (SAP) and the clinical  study  report. Addi tional exploratory  analyses of the data will be 
conducted as deemed appropriate.
The ISA SAP will be finalized prior to unblinding, and it will include a more technical and 
detailed descript ion of the statist ical analyses described in this section. 
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
289.4.1. General Considerations
The m aster protocol  CPMP describes t he primary endpo int and analyses. 
The m aster protocol  CPMP and DSA CPMP(1) describe the secondary and tertiary /expl oratory  
endpo ints and analyses.
Any borrowing of placebo or treatment effect informatio n will be specified in the ISA SAP. 
9.4.2. Pharmacokinetics and Pharmacodyn amics
The observed plasma concentrations for LY3556050 will be reported graphically and 
descri ptively. 
Model -based PKand PKPD analyses may be conducted to characterize the PKof LY3556050 in 
participants wi th OA and to explore exposure- response relationships for various PDmeasures 
using suitable popul ation analysis so ftware .Participant factors m ay be invest igated to assess 
their effects on model parameters. Additional analyses may  be conducted, as needed. 
Data from this study may be pooled wi th data from other studies , if appropri ate. Addit ional 
details on PK and PK PD analyses will  be provi ded in a separate PKPD analysis plan.   
A limited number of pre specif ied individuals who are not part of the blinded study  team and do 
not have direct site contact, data entry, or data validation responsibilit ies,may receive access to 
unblinded data, prior to the interim or final database lock, in order to init iate the final population 
PKPD model devel opment processes. This will be describ ed in the unblinding plan . Inform ation 
that may  unblind the study  during the analyses will not be reported to study sites or blinded study 
team  until the study  has been unblinded.
9.4.3. Tertiary/Exploratory
All safet y analyses will be made on the safety population.Descript ive statistics  
 will be conducted as deemed 
appropriate. Confounding factors , such as beta blo cker therapy ,may be adjusted in the statistical 
modelsfor safet y analyses. Subgroup analyses of cardi ovascular safet y endpo ints with beta 
blocker therapy  may be conducted accordingly.
9.4.4. Biomarker s 
Consistent wi th the master protocol CPMP objectives, exploratory  fluid and di gital biomarker 
analyses may be conducted on sam ples and data collected during the study .  
Interim Analyses 
Interim analys es may  be conducted for internal decisio n-making. Unblinding and interim 
analysis details may be specified in the unblinding plan sect ion of the SAP or in a separat e 
docum ent. 
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
2910. Supporting Documentation and Operational Considerations
Appendix 1: Clinical Laboratory Tests
The m aster protocol  CPMP describes tests that may be performed at additional t imes noted in the 
SoA for this ISA. This table describes tests unique for ISA OA0 3.  
Chemistry Additional Thyroid Tests Other SST-Regulated Hormone s Other Tests
Cystatin -C Free Triiodo thyronin e (FreeT3) Growth ho rmone Amylase
TSH Total Triiodothyronine (T3) I nsulin -like Growth Factor -1(IGF -1) Lipase
Free Thyroxine ( FreeT4) Prolactin LY3556050 concentration
Total Thyroxine ( T4) Gastrin Serum pregnancy test
Glucagon HbA1c
Insulin
Abbreviations: HbA1c = glycated hemoglobin; SST = somatostatin; TSH = thyroid -stimulating hormone.
Thyroid Safety Follow- Up
TSH
Free Triiodothyronine (FreeT3)
Total Triiodothyronine (T3)
Free Thy roxine (FreeT4) 
Total Thy roxine (T4)
Thyroglobulin
Anti-Thyroglobulin
Anti-Thyroperoxidase Antibodies
Iodine
Abbreviation:  TSH = thyroid -stimulating hormone.
CCI
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
30
Appendix 2: Definitions of Reproductive Requirements and 
Contraceptive Guidance
Women
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Woman not of Childbearing Potential ( non-WOCBP)
Women in the fo llowing categori es are not considered WOCBP:
premenarchal
premenopausal female that is infert ile due to surgical sterilizat ion, or
postmenopausal .
Surgical sterilizat ion examples include
hysterectomy 
bilateral  oophorectomy , or
tubal  ligation.  
Postmenopausal  isdefined as ei ther
a wom an at least 40 y ears of age with an intact uterus, not on hormone therapy , who has 
cessat ion of menses for at least 1 y ear wi thout an alternat ive medical cause, AND a 
follicle -stimulat ing hormone >40 mIU/mL
a wom an55 or ol der not on horm one therapy , who has had at l east 12 m onths of 
spon taneous am enorrhea, or
a wom anat least 55 y ears of age with a diagnosis of menopause prior to starting hormone 
replacement therapy .
For individuals wit h permanent infert ility due to an alternate medical cause other than the above, 
(e.g., Mü llerian agenesi s, androgen insensit ivity), investi gator di scret ion shoul d be applied to 
determining study  entry .
Note:  D etermina tion can com e from the si te personnel’s review of the participant’s medical 
records, medical examinat ion, or medical history  interview.
Participation in the Study
Womennot of childbearing potential andof childbearing potenti al may  parti cipate in thi s study .
Womennot of childbearing potential include those who 
have a congenital ano maly such as Müllerian agenesis 
areinfert ile due to surgical sterilizat ion, or 
are postmenopausal.  
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
31At least 6 weeks must have passed after surgical bilateral oophorectomy wit h or without 
hysterectomy, or after tubal ligat ion.
Women of childbearing potential must test negative for pregna ncy prior to ini tiation of treatment 
as indicated by  a negat ive serum pregnancy  test at the screening visit followed by a negat ive 
urine pregnancy test within 24 hours prior to exposure.
Women of childbearing potential who are completely abstinent or in a same-sex rel ationship ,as 
part of their preferred and usual lifest yle,must agree to either remain abst inent or stay  in a 
same -sex rel ationship wi thout sexual relat ionships with males.
All other wom en of childbearing potential must agree to use 1 highly effective method of 
contraception (less than 1% failure rate) , or a combinat ion of 2 effect ive methods of 
contraception , for the enti rety of the study . 
Abstinence or contraception must continue for 3 days after the l ast dose of intervent ion.
Acce ptable Methods of Contraception
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptive pill and mini -pill
implanted or injectable contracepti ves
contraceptive patch (only for women <198 pounds or 90 kg)
total abst inence
vasectomy  if they are the only sexual partner
fallopian tube implants if confirmed by hysterosalpingogram
combined contraceptive vaginal ring ,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are not limited to
male or female condoms with spermicide
diaphragms wit h spermicide or cervical sponges
barrier m ethod wi th use of a spermicide
ocondom  with spermicide
odiaphragm  with spermicide, or
ofemale condo m with spermicide .
Note:  The ba rrier method m ust include use of a spermicide (i.e., condom wit h spermicide, 
diaphragm  with spermicide, female condom with spermicide) to be considered effect ive.  
Not Acceptable Methods of Contraception
Ineffective methods of contraception co mprise of
spermicide alo ne 
immuno -contraceptives
periodic abst inence
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
32fertilit y awareness 
ocalendar m ethod 
otemperature m ethod 
ocombinat ion of calendar and temperature method
ocervical mucus, or
osymptothermal
withdrawal
post coi tal douche , or
lactati onal amenorrhea .
Men
Men are not required to use contraception during study  parti cipat ion.
Collection of Pregnancy Information
Male participants with partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive LY3556050 .
After obtaining the nece ssary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partner’s pregnancy. 
The female partner will also be fo llowed to determine the outcome of the pregnancy . Informati on 
on the status of the mother and child will be forwarded to the sponsor. Generally, the fo llow-up 
will be no longer than 6 to 8 weeks fo llowing the estimated delivery  date. Any  termin ation of  the 
pregnancy will be reported regardless of gestational age, fetal status (presence or absence of 
anomalies) orindicat ion for the procedure. 
Female participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this study . The init ial informat ion will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning of a participant's 
pregnancy. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, fo llow-up will not be required for longer than 6 to 8 weeks 
beyo nd the est imated delivery date. Any terminat ion of pregnancy will be reported, including 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth (occurring at 
≥20weeks gestational age) is always considered to be an SAE and will be reported as such. 
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
33Any poststudy  pregnancy -related SAE considered reasonably  related to the study  intervent ion by 
the invest igator will be reported to the sponsor as described in the master protocol CPMP 
Secti on8.3.4 . While the invest igator is not obligated to actively seek this informat ion in former 
study  participants, he or she may learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while parti cipat ing in the study  will be withdrawn 
from the study  and will  follow the standard discontinuat ion process.  
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
34
Appendix 3:  Provisions for Changes in Study Conduct During 
Exceptional Circumstances
Implementation of this appendix
The changes to procedure s described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by  the sponsor.
Exceptional circumstances
Except ionalcircumstances are rare events may cause di srupt ions to the conduct of the study .
Examples include pandemics or natural disasters . These disrupt ions may limit the abili ty of the 
investigators, participants, or both to attend on -site visi ts or to conduct pl anned study  procedures.
Implementing changes under exceptional circumstances
In an except ional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulat ions. 
Ethical Review Boards (ERBs) and regulatory  bodies will be notified as early as possible to 
communicate implementati on of  changes in study  conduct due to exceptional circumstances. To 
protect the safet yof study  partici pants, urgent changes may be implemented before 
communicat ionto ERBs and regulatory  bodies.Lilly will report all changes as soon as possible 
following implementati on.If approval o f ERBs, regul atory  bodi es, or both i s requi red per l ocal 
regul ations, the site must retain confirmat ion of this approval in the study  records.
Additional written guidance will be provi ded by  the sponsor in the event written approval is 
granted for changes in study  conduct . 
Considerations for making a change
The prevailing considerat ionfor making a change is e nsuring the safet y of study  parti cipants.
Addit ional important considerat ions for making a change are
Good Clinical Pra ctice co mpliance, and
minimizat ion of ri sk to study  integrity. 
Such changes are intended to
mitigate ri sks of parti cipants missing visit s
allow participants to continue safely in the study, and
maintain the data integrit y of the study . 
Informed Consent
If these ci rcumstances occur , additional consent from the participant willbe obtained , if 
applicable, for:
participati onin remote vi sits
additional study  intervent iondispensed to a participant during an extended visit window , 
or
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
35alternate delivery  of study  interventi on and ancillary  supplies, as well as provisio n for
their personal  or m edical informat ion required prior to implementation of these 
activit ies.
Changes in Study Conduct
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regul ations, are not allowed.
The fo llowing changes in study  conduct will not be considered protocol deviat ions. Missing data 
will be captured as protocol deviat ions.
Remote visits
In source documents an d the CRF, the study  site shoul d capture the visit method, with a specific 
explanat ion for any  data missing because of missed in -person site visits. 
Telemedicine:   Telephone or techno logy-assisted virtual visit s, or both, are acceptable to 
complete appro priate assessments. 
Assessments to be completed in this manner include, but are not limited to ,individual 
safet y follow-up.
Mobile healthcare: Healthcare visi ts may be perform ed at l ocati ons other than the study  
site (for example, participant’s home) when participants cannot travel to the site due to an 
exceptional circumstance. Such visit s will be perform ed by a m obile heal thcare provi der. 
Procedures performed at such visit s include, but are not limited to ,collection of blood 
samples, physical examinat ions, ECGs, vital signs , intervent ion accountabilit y and 
compliance , AE collect ion, and collection o f healt h informat ion.
Other local procedure s:Laboratory  draws may be done at an alternate location in 
exceptional circumstances .
Regardless of the ty pe of  remote visi ts implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged. 
Every effort shoul d be made to enable part icipants to return to onsite visits as soon as reasonably 
possible, while ensuring the safet y of both the participants and the site staff.
Local Laboratory Testing
Local  laboratory  testing m ay be conducted in lieu of central  laboratory  testing. The l ocal 
laboratory  must be qualified in accordance with applicable local regulat ions.
If local testing is used ,PKand exploratory  biomarker sam ple collect ionmay notoccur .
Investigational Product and Ancillary Supplies (in cluding participant diaries)
When a participant is unable to go to the site to receive study  supplies during norm al onsi te 
visits, the site should work with the sponsor to determine appropriate actions. These act ions may 
include:
asking the participant to go to the site and receive study  supplies from  site staff 
without com pletion of a full study  visit,
CONFIDENTIAL Protocol  number H0P-MC-OA03 (a)
36asking the participant’s designee to go to the site and receive study  supplies on a 
participant’s behalf, and
arranging deliv ery of study  supplies .
Alternate delivery  of invest igational product should be performed in a manner that does not 
compromise treatment blinding and ensures product integrit y. 
The exist ing protocol requirements for product accountabilit y remain unchanged, including 
verification of parti cipant’s receipt of study  supplies.
When delivering supplies to a locat ion other than the study  site, the invest igator, sponsor, or both 
shoul d ensure oversight of the shipping process to ensure accountabilit y and product qualit y (that 
is, storage conditions maintained and intact packaging upon receipt).
Instructi ons shoul d be provi ded to the participant on how to return any  unused or com pleted 
study  supplies.
For parti cipants whose visits have extended windows, additional study  interventi onmay need to 
be provided to avoid study  intervent ioninterrupti on and m aintain overall integrit y of the study .
Adjustments to Visit Windows
Participants shoul d com plete the SoA as described in the master protocol CPMP, DSA CPMP(1) 
and this ISA whenever possible and safe to do so. To maximize the possibilit y that visi ts are
conducted at the clinical site , the visi twindows may be adj usted to minimiz e missing data and 
preserv ethe intended conduct of the study .Adjustments to the visit windows will be disc ussed 
with,and approved by ,the sponsor prior to anychanges.
Documentation
Changes to study  conduct will be docum ented .
Sites will ident ify and document the details o f how participants, visits t ypes, and conducted 
activit ies were affected by except ional circumstances. 
Dispensing and shipment records of intervent ionand rel evant communicat ions, including 
delegation, shoul d be filed wit h site study  records.
Source documents generated at a location other than the study site should be part of the 
investig ator’s source docum entati on and shoul d be transferred to the site in a secure and timely 
manner.
The study  site shoul d capture specific explanat ions for any  missing data and other protocol 
deviat ions in source documents. 
Although protocol deviations may be unavo idable in an exceptional circumstance, 
docum entati on of  protocol  deviat ions and missing data will be important for data analysis and 
reporting.
CONFIDENTIAL Protocol  number H0P- MC-OA03 (a)
37
Appendix 4: Abbreviations
Term Definition
BID twice daily
DSA disease -state adden dum
eGFR estimated glomerular filtration rate
ERB Ethical Review Board
FACTS Fixed and Adaptive Clinical Trial Simulator software tool
ISA intervention -specific appendix
OA osteoarthritis
PD pharmacodynamic
PK pharmacokinetic
PKPD pharmacokinetic -pharmacodynamic
PRinterval During an ECG, t he period , measured in milliseconds, that extends from the beginning 
of the P wave until the beginning of the QRS complex .
QRS During an ECG, a combination of the Q wave, R wave and S wave , repr esenting 
ventricular depolarization.
QT During an ECG, the QT interval is the time from the start of the Q wave to the endo of 
the T wave.
QTcF QT interval using Fridericia’s correction formula
SST somatostatin
SSTR somatostatin receptor
TSH thyroid-stimulating hormone
WOCBP woman/women of childbearing potential
WOMAC Western Ontario and McMaster University Osteoarthritis Index
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 4 - F e b - 2 0 2 1  2 0 : 5 8 : 0 5  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e d
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 4 - F e b - 2 0 2 1  2 3 : 4 7 : 3 5  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e dC CI
P P DP P D
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 2 - M a r - 2 0 2 1  0 2 : 0 9 : 1 5  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e d
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 2 - M a r - 2 0 2 1  2 2 : 4 1 : 4 3  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e dP P D
P P DC CI
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 3 - M a r - 2 0 2 1  1 9 : 5 8 : 5 3  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e d
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 3 - M a r - 2 0 2 1  1 9 : 5 9 : 0 2  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e dP P D
P P DC CI